AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04203056
Drug: ARI-ORAL
RxNorm normalized name: Ovis aries whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral aripiprazole
Trial: NCT03003468
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg IV
Trial: NCT04568031
Drug: 0.9% (w/v) saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subjects in placebo will have that route of Administration as Intramuscular 0.9% (w/v) saline on V2 and V6.
Trial: NCT02833766
Drug: anti-EGFR-IL-dox
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line treatment with anti-EGFR-IL-dox, given at a dose of 50 mg/m2 intravenous, on day 1 of each cycle, cycle length is 28 days
Trial: NCT01565850
Drug: DRV
RxNorm normalized name: Urinal Male Drv RTLPC23201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV 800 mg (2 × 400 mg tablets) administered orally once daily
Trial: NCT01565850
Drug: DRV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV placebo tablet administered orally once daily
Trial: NCT01471639
Drug: intranasal ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg
Trial: NCT03252418
Drug: Ascorbic Acid 500 MG
RxNorm normalized name: ascorbic acid 500 MG
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ascorbic acid is vitamin that can cause gingival depigmentation
Trial: NCT00446199
Drug: 0.5mg DRSP / 0.5mg E2 (BAY86-4891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet \[0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
Trial: NCT00446199
Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
Trial: NCT00446199
Drug: Estradiol (E2 0.3mg)
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet \[17β-estradiol (E2 0.3mg)\] per day taken orally for 3 cycles (28 days per cycle).
Trial: NCT00446199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
Trial: NCT02912845
Drug: KamRAB - HRIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wound infiltration or IM injection
Trial: NCT01195792
Drug: GSK1521498
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1521498 2mg or 5mg will be given for up to 35 days and subjects will be assessed weekly
Trial: NCT00280462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01195792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given for up to 35 days and subjects will be assessed weekly
Trial: NCT00321828
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 400 mg/m2 IV bolus over 2-4 minutes then 2400 mg/m2 IV continuous infusion over 46 hours on day 1 every 14 days until excessive toxicity or disease progression
Trial: NCT00321828
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: leucovorin 400 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
Trial: NCT01590875
Drug: Adenosine arm
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the adenosine arm, 25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose. In the observation arm, 25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation.
Trial: NCT00573157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered at a dose of 150 mg SC twice weekly for 4 weeks followed by 150 mg SC once weekly for 48 weeks.
Trial: NCT00573157
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.
Trial: NCT02944383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets administered orally once daily, for 12 weeks.
Trial: NCT00915928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dayli for 3 months
Trial: NCT03602781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo at a dose setting of 75 mcg/kg IBW/hr
Trial: NCT02402114
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 120 mg Hydrocortisone given orally one time.
Trial: NCT02058212
Drug: ascorbate 1000mg, vitamin E 400, zinc and selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome
Trial: NCT01183221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Placebo
Trial: NCT03752827
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection into subacrominal space
Trial: NCT04581512
Drug: EP0042
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP0042 Oral 20 mg 50 mg capsules
Trial: NCT00003521
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Soft Tissue Sarcoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT00937378
Drug: SER120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal Spray, once a day
Trial: NCT01495156
Drug: Placebo/Adjunctive SGA treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the placebo /adjunctive SGA group will receive placebo for the entire trial in addition to the adjunctive SGA.
Trial: NCT00852969
Drug: Active Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Niacin tablets once per day
Trial: NCT02957643
Drug: Iron
RxNorm normalized name: Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral treatment
Trial: NCT02595424
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02349243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg placebo, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
Trial: NCT03247517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered once daily
Trial: NCT03247517
Drug: 200mg SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg SPN-812 was administered once daily and compared to placebo
Trial: NCT03247517
Drug: 400mg SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg SPN-812 was administered once daily and compared to placebo
Trial: NCT00678041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
Trial: NCT02358343
Drug: Antidepressant Drug Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The site investigators will prescribe sertraline drug at a starting dose of 25 mg oral tablets. Dose titration will be implemented using standardized assessments of depressive symptoms and drug side effects; and the research team and the patient make joint decisions to maintain, increase, or decrease the dose. This will help establish the highest effective but tolerable dose tailored for each patient. The QIDS-SR scale will be used to assess the clinical response for dose titration. The FIBSER scale will be used to assess side effects and the degree to which they interfere with day-to-day functions. The participant-specific dose at week 6, up to a maximum of 200 mg/d, will be continued for the remaining 6 weeks.
Trial: NCT03861403
Drug: TRX518
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by IV infusion
Trial: NCT03861403
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by IV infusion
Trial: NCT00226421
Drug: Oxymorphone Extended Release
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02015559
Drug: mucoadhesive oral wound rinse
RxNorm normalized name: MuGard Mucoadhesive Oral Wound Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03275922
Drug: Placebo ZNS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Zolmitriptan Nasal Spray
Trial: NCT03275922
Drug: ZNS
RxNorm normalized name: ZnSO4 3 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan Nasal Spray
Trial: NCT04054960
Drug: Levodopa tablet
RxNorm normalized name: Levodopa Tablets
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: We will give 3 tablets of Levodopa-Carbidopa (100/25).
Trial: NCT04132336
Drug: Naproxen sodium/Caffeine (BAY2880376)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral, single dose
Trial: NCT04132336
Drug: Naproxen sodium (Aleve)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, oral, single dose
Trial: NCT04132336
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, oral, single dose
Trial: NCT04132336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral, single dose
Trial: NCT00433290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo every day (QD), by mouth (PO) for 13 weeks
Trial: NCT01107457
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT04008186
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg tablet
Trial: NCT00974974
Drug: IPX066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: extended-release carbidopa-levodopa capsules
Trial: NCT00974974
Drug: IR CD-LD
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immediate-release carbidopa-levodopa tablets
Trial: NCT01892657
Drug: Facial Moisturizer with SPF 50+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+
Trial: NCT02613013
Drug: Proparacaine
RxNorm normalized name: proparacaine
DrugBank: Proparacaine (DB00807)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
Trial: NCT02773459
Drug: MEK162+capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In phase 1 part: capecitabine(mg/m2) will be given twice a day, 2 week on/1week off Q 3weeks + MEK162 twice a day, continuously, starting at 1000mg/m2 and 30mg/m2 respectively. Expansion part will be treated with the dose found at phase 1 part.
Trial: NCT00713999
Drug: Treatment with anti-STI and anti-schistosoma regimens
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and breastfeeding women) Anti-schistosoma regimen: Praziquantel 40mg/kg
Trial: NCT00132093
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01916590
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01736241
Drug: LY3053102
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01736241
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00688376
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the 12-week Double-Blind Phase, subjects will receive matching placebo tablets (3, 5, of 10 mg) once daily.~During the 12-week Blinded Extension Phase, all subjects will receive active treatment (donepezil).
Trial: NCT02770885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with Sodium Chloride 0.9% (Placebo) for 3 weeks.
Trial: NCT03837938
Drug: Levopront® syrup 30 mg/5 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1).
Trial: NCT03837938
Drug: Libexin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1). No chewing.
Trial: NCT01415765
Drug: MLN4924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: 150mg/m2 IV (in the vein) on days 1,4,7,11 of each 21 day cycle Part B: variable dose levels IV on days 1,5 each 21 day cycle
Trial: NCT01415765
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV on day 5 of each 21 day cycle
Trial: NCT00592839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for 0.3 mg and 0.625 mg tablets
Trial: NCT01415765
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CIV on days 1-4 of each 21 day cycle
Trial: NCT00004230
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02858258
Drug: R-CHOP/R-DHAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)
Trial: NCT01131572
Drug: N-acetylcysteine NAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine in the treatment of Bulimia Nervosa
Trial: NCT02858258
Drug: ASCT conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASCT conditioning THAM or BEAM, stratified per site before trial activation at site~THAM (TBI (total body irradiation), Ara-C, Melphalan) or~BEAM (BCNU, Etoposide, Cytarabine, Melphalan)
Trial: NCT00308685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00816361
Drug: MEDI-573
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.
Trial: NCT03598192
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil has been included in Arm/Group Descriptions
Trial: NCT00128414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets identical in colour, shape, and taste were provided in blister packs.
Trial: NCT03080415
Drug: Combined Therapy SOF and DCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 whole or half tablet sofosbuvir and 1 whole or half tablet daclatasvir per day~SOF dosage: 400 mg/day for greater than 45 kg weight patients; 200 mg/day for 17 kg to 45 kg patients~DCV dosage: 60 mg/day for greater than 45 kg weight patients; 30 mg for 17 kg to 45 kg patients
Trial: NCT00436709
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00436709
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03233230
Drug: M2591 25 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 12 weeks.
Trial: NCT03233230
Drug: M2951 75 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 75 mg of M2951 orally QD for 12 weeks.
Trial: NCT03233230
Drug: M2951 50 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 50 mg of M2951 orally twice daily (BID) for 12 weeks.
Trial: NCT03233230
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo matched to M2951 orally for 12 weeks.
Trial: NCT01019928
Drug: AZD1386
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 95 mg, oral solution, single dose
Trial: NCT01019928
Drug: Placebo to AZD1386
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral solution, single dose
Trial: NCT02838810
Drug: Nucleoside analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleoside analogues
Trial: NCT00643136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules twice daily for 28 days
Trial: NCT00757848
Drug: AZD9668 Placebo equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Match placebo to 60 mg, oral tablet, twice daily for 28 days
Trial: NCT00845000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule, oral, at hour 0 of treatment period
Trial: NCT00845000
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
Trial: NCT01831453
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: soft gelatinous capsules filled with isopropylmyristate oil
Trial: NCT02581007
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.
Trial: NCT02516904
Drug: CD101 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antifungal
Trial: NCT00001713
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03812328
Drug: SelK2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V., single-dose
Trial: NCT03461861
Drug: AGB101 220 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGB101 oral dose of 220 mg/day capsule, given as once-daily dosing.
Trial: NCT03512262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abaloparatide-matched placebo.
Trial: NCT02013375
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (50 mg/kg IBW) IV, over approximately 1-2 hours, is given on Day 3 post-transplantation (ideally between 60 and 72 hours after marrow infusion) and on Day 4 (approximately 24 hours after Day 3 cyclophosphamide).
Trial: NCT03045471
Drug: R-EPOCH
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Etoposide: a topoisomerase inhibitor from the group of epipodofyllotoxins; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.